Development and Internal Validation of a Novel Prognostic Score in Metastatic Colorectal Cancer: A Comparative Retrospective Cohort Study with the Glasgow Prognostic Score and Gustave Roussy Immune Score
Open Access
- 29 June 2026
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5074
Abstract
Background: Reliable prognostic stratification is essential in metastatic colorectal cancer (mCRC), yet current inflammation-based scores do not fully integrate systemic inflammation, tumor burden, and clinical characteristics. Objective: This study aimed to develop a novel prognostic score integrating clinical, tumor burden, and inflammatory parameters in patients with mCRC and to compare its performance with the Glasgow Prognostic Score (GPS) and Gustave Roussy Immune Score (GRIm). Materials and Methods: This retrospective single-center study included 310 patients with mCRC treated between 2015 and 2025. GPS and GRIm were calculated. The novel prognostic score was constructed using seven equally weighted prognostic variables encompassing clinical characteristics, tumor burden, and laboratory parameters. Survival analyses were performed using Kaplan–Meier and Cox regression. Model performance was assessed using AUC, reclassification, calibration, and decision curve analysis. Results: Most patients had ECOG PS 0–1 (96.1%), left-sided tumors (76.1%) and synchronous metastases (79.0%). The median follow-up was 23.6 months. Both GPS and GRIm were independent prognostic factors for OS. GPS demonstrated superior discriminative performance compared with GRIm (AUC for 24-month OS: 0.697 vs. 0.620; p = 0.005). The novel score stratified median OS into low-, intermediate-, and high-risk groups as 40.9, 25.4, and 11.5 months, respectively (p < 0.001). The novel model outperformed GPS and GRIm (AUC: 0.768) and improved reclassification. Bootstrap-based internal validation demonstrated low optimism and good calibration. Conclusions: The novel prognostic score integrating clinical, inflammatory, and tumor burden parameters demonstrated superior prognostic performance compared with GPS and GRIm in mCRC. This score may serve as tool for individualized risk stratification.Keywords
This publication has 22 references indexed in Scilit:
- Prognostic role of lymph node-related indices and development/internal validation of a novel nomogram in colorectal cancer patients with synchronous lung metastases: a study based on the SEER databaseTranslational Cancer Research, 2026
- Development and validation of an AI-augmented deep learning model for survival prediction in de novo metastatic colorectal cancerDiscover Oncology, 2025
- Mechanisms of metastatic colorectal cancerNature Reviews Gastroenterology & Hepatology, 2024
- Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancerBMC Cancer, 2024
- Prognostic significance of the Gustave Roussy immune (GRIm) score in cancer patients: a meta-analysisAnnals of Medicine, 2023
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Prognostic Significance of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Metastatic Colorectal CancerJournal of Gastrointestinal Cancer, 2021
- Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosisAnz Journal of Surgery, 2020
- Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancerESMO Open, 2020
- The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancerCancer Treatment Reviews, 2013